<DOC>
	<DOCNO>NCT00003179</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use surgery without medroxyprogesterone may effective way prevent development endometrial cancer patient endometrial hyperplasia . PURPOSE : Phase II trial compare effectiveness surgery alone medroxyprogesterone follow surgery prevent endometrial cancer patient endometrial hyperplasia .</brief_summary>
	<brief_title>Surgery Plus Medroxyprogesterone Preventing Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine joint occurrence atypical hyperplasia adenocarcinoma patient diagnose initial biopsy complex atypical hyperplasia . - Compare histologic response rate patient atypical endometrial hyperplasia treat oral medroxyprogesterone acetate ( Provera ) vs intramuscular medroxyprogesterone acetate suspension ( Depo-Provera ) . OUTLINE : This randomize , two-part study . - Part A : Patients undergo immediate hysterectomy . - Part B : Patients randomize 1 2 arm . - Arm I : Patients receive oral medroxyprogesterone acetate ( Provera ) daily 3 month . - Arm II : Patients receive medroxyprogesterone acetate suspension ( Depo- Provera ) intramuscularly monthly 3 month ( day 1 , 31 , 62 ) . Patients undergo hysterectomy end third month . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A minimum 360 patient part A 140 patient ( 70 per arm ) part B accrued study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm atypical endometrial hyperplasia recommend treatment either : An immediate hysterectomy ( Part A ) OR A threemonth delay prior hysterectomy randomized choice treatment oral medroxyprogesterone acetate ( Provera ) medroxyprogesterone acetate suspension ( DepoProvera ) 3 month ( Part B arm I II ) Diagnosed dilation curettage , Novak curettage , Vabra aspirate Pipelle endometrial biopsy No recognize endometrial carcinoma Must consider inoperable PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Granulocyte count least 1,500/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 2 time normal Cardiovascular No prior thrombophlebitis thromboembolic phenomenon No prior cerebrovascular disorder Other : No prior concurrent malignancy except nonmelanoma skin cancer carcinoma situ uterine cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>endometrial cancer</keyword>
</DOC>